上海医药：附属公司泼尼松龙片通过仿制药一致性评价

财中社04-24

　　4月24日，上海医药（601607/02607）发布公告，公司下属天津信谊津津药业有限公司的泼尼松龙片通过仿制药一致性评价。

　　泼尼松龙片主要用于过敏性与自身免疫性炎症性疾病，胶原性疾病。截至本公告日，公司针对该药品的一致性评价已投入研发费用约800万元。

　　2025年，上海医药实现收入2835.80亿元，归母净利润57.25亿元。

（文章来源：财中社）

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2629176718?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-04-24 18:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2629176718","market":"sh","top_or_hot":-1,"title":"上海医药：附属公司泼尼松龙片通过仿制药一致性评价","media":"财中社","content":"<html><body><div>\n<p>　　4月24日，<span><a href=\"https://laohu8.com/S/601607\">上海医药</a></span>（601607/02607）发布公告，公司下属天津信谊津津药业有限公司的泼尼松龙片通过仿制药一致性评价。</p><p>　　泼尼松龙片主要用于过敏性与自身免疫性炎症性疾病，胶原性疾病。截至本公告日，公司针对该药品的一致性评价已投入研发费用约800万元。</p><p>　　2025年，<span href=\"http://quote.eastmoney.com/unify/r/116.02607\" target=\"_blank\" web=\"1\"><a href=\"https://laohu8.com/S/02607\">上海医药</a></span>实现收入2835.80亿元，归母净利润57.25亿元。</p><p>（文章来源：财中社）</p> </div></body></html>","source":"stock_eastmoney","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>上海医药：附属公司泼尼松龙片通过仿制药一致性评价</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n上海医药：附属公司泼尼松龙片通过仿制药一致性评价\n</h2>\n\n<h4 class=\"meta\">\n\n</h4>\n\n</header>\n<article>\n<html><body><div>\n<p>　　4月24日，<span><a href=\"https://laohu8.com/S/601607\">上海医药</a></span>（601607/02607）发布公告，公司下属天津信谊津津药业有限公司的泼尼松龙片通过仿制药一致性评价。</p><p>　　泼尼松龙片主要用于过敏性与自身免疫性炎症性疾病，胶原性疾病。截至本公告日，公司针对该药品的一致性评价已投入研发费用约800万元。</p><p>　　2025年，<span href=\"http://quote.eastmoney.com/unify/r/116.02607\" target=\"_blank\" web=\"1\"><a href=\"https://laohu8.com/S/02607\">上海医药</a></span>实现收入2835.80亿元，归母净利润57.25亿元。</p><p>（文章来源：财中社）</p> </div></body></html>\n\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"http://finance.eastmoney.com/a/202604243718154291.html\">财中社</a> </p>\n\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n</div>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0184","symbol_name":"上海国资改革","start_time":0,"source_url":"http://finance.eastmoney.com/a/202604243718154291.html","article_id":"2629176718","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2629176718","pubTimestamp":1777024920,"columns":[],"sourceInfo":{"source_id":"stock_eastmoney","name":"东方财富"},"weMediaInfo":null,"summary":"4月24日，上海医药（601607/02607）发布公告，公司下属天津信谊津津药业有限公司的泼尼松龙片通过仿制药一致性评价。泼尼松龙片主要用于过敏性与自身免疫性炎症性疾病，胶原性疾病。截至本公告日，公司针对该药品的一致性评价已投入研发费用约800万元。2025年，上海医药实现收入2835.80亿元，归母净利润57.25亿元。","collect":0,"end_time":0,"defaultTopTitle":"eastmoney.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"601607":"上海医药","BK0184":"上海国资改革","BK0187":"一线龙头","BK0028":"国家队","BK0097":"医药电商","BK0099":"上海本地重组","02607":"上海医药","BK0020":"浦东新区","BK1197":"保健护理产品经销商","BK0209":"零售","BK0183":"MSCI概念","BK0196":"行业龙头","BK0188":"融资融券","BK0012":"证金概念","BK0175":"白马股"},"translate_title":"Shanghai Pharmaceuticals: Subsidiary Prednisolone Tablets Passed Generic Drug Consistency Evaluation","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"601607":1.5,"02607":1.5},"content_text":"4月24日，上海医药（601607/02607）发布公告，公司下属天津信谊津津药业有限公司的泼尼松龙片通过仿制药一致性评价。　　泼尼松龙片主要用于过敏性与自身免疫性炎症性疾病，胶原性疾病。截至本公告日，公司针对该药品的一致性评价已投入研发费用约800万元。　　2025年，上海医药实现收入2835.80亿元，归母净利润57.25亿元。（文章来源：财中社）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2629176718","isCrawlerRequest":true}